Drug metabolite screening and synthesis

Metabolite screening, biotransformation and production

Our process begins with screening using two specialised panels:

• Wild-type strain panel: comprises 55 fungi and bacteria strains for broad-spectrum metabolite identification
• CYP panel: comprises 119 human wild-type and bacterial CYP variants (e.g., CYP3A4, 2D6, CYP102A1), targeting oxidative metabolite synthesis.

Next, we proceed with microbial biotransformation:

• Scale-up to 10L fermenters for initial biotransformation, followed by purification and structure elucidation
• We also offer chemical oxidation or glucuronidation as additional synthesis possibilities.

Finally, we perform large-scale production:

• Up to 100L fermenters for gram-scale production of drug metabolites, ensuring high yields for further testing and development.